Moolec Science (MLEC) & Its Rivals Financial Contrast

Moolec Science (NASDAQ:MLECGet Free Report) is one of 673 public companies in the “Holding & other investment offices” industry, but how does it compare to its rivals? We will compare Moolec Science to related companies based on the strength of its institutional ownership, earnings, valuation, analyst recommendations, profitability, dividends and risk.

Earnings and Valuation

This table compares Moolec Science and its rivals gross revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Moolec Science $5.62 million -$7.31 million -4.38
Moolec Science Competitors $1.01 billion $81.23 million 62.38

Moolec Science’s rivals have higher revenue and earnings than Moolec Science. Moolec Science is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Insider & Institutional Ownership

0.1% of Moolec Science shares are held by institutional investors. Comparatively, 54.2% of shares of all “Holding & other investment offices” companies are held by institutional investors. 19.9% of Moolec Science shares are held by insiders. Comparatively, 26.7% of shares of all “Holding & other investment offices” companies are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings and recommmendations for Moolec Science and its rivals, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Moolec Science 0 0 1 0 3.00
Moolec Science Competitors 128 730 961 19 2.47

Moolec Science currently has a consensus price target of $6.00, suggesting a potential upside of 585.71%. As a group, “Holding & other investment offices” companies have a potential upside of 54.43%. Given Moolec Science’s stronger consensus rating and higher possible upside, research analysts plainly believe Moolec Science is more favorable than its rivals.

Volatility & Risk

Moolec Science has a beta of -0.54, meaning that its stock price is 154% less volatile than the S&P 500. Comparatively, Moolec Science’s rivals have a beta of 0.03, meaning that their average stock price is 97% less volatile than the S&P 500.

Profitability

This table compares Moolec Science and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Moolec Science -129.97% -97.95% -27.91%
Moolec Science Competitors -17.66% -43.09% -0.30%

Summary

Moolec Science rivals beat Moolec Science on 10 of the 13 factors compared.

About Moolec Science

(Get Free Report)

Moolec Science SA, a science-based food ingredient company, focuses on developing real animal proteins in plants using molecular farming. It offers Chymosin SPC, a dairy ingredient; GLA SONOVA, a nutritional oil; POORK+, a plant-based, animal meat free ingredient with porcine proteins in soybeans; and BEEF+, a meat replacement product. It operates in the United States, Europe, and South America. The company was founded in 2020 and is based in Luxembourg.

Receive News & Ratings for Moolec Science Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moolec Science and related companies with MarketBeat.com's FREE daily email newsletter.